Monday July 16, 2018
Home India Stanford Stud...

Stanford Study Ranks India among the Laziest People in the World

A recent study by a group of researchers at Stanford have revealed that Indians are among the laziest people in the world

0
//
72
Laziest People
Indians average just 4,297 steps a day. Wikimedia
Republish
Reprint
  • A Stanford study has ranked India 39 in the world for the laziest people 
  • China, and particularly Hong Kong, has the most active people
  • The research also found out that Indian women walk even less than men

July 17, 2017: Researchers at Stanford University carried out a study on 46 countries to find out the levels of laziness. In its finding, Indians ranked 39 and thus among the laziest people.

Indian people average only about 4,297 steps a day. It was also observed that women in India walk much less than men. While men registered an average of 4,606 steps daily, women averaged 3,684 steps.

The world average is 4,961 steps. The Americans stood at an average of 4,77,4 steps daily.

ALSO READ: Cosmetic Industry is Booming: Thanks to Young Indians!

The most active people, according to the research, are the Chinese and mainly the ones in Hong Kong. Other notably active people are from Ukraine and Japan. The people in these countries walk more than 6,000 steps daily, mentioned ANI report.

With a daily average of just 3,513 steps, the Indonesians ranked as the laziest people in the world. Other laziest countries include Malaysia and Saudi Arabia. These countries have an average of fewer than 3,900 steps.

The researchers at Stanford University installed step-counters in smartphones and used that information for the research. 700,000 people from 46 different countries were part of the research, which has been published in the journal called Nature.

– Prepared by Saksham Narula of NewsGram. Twitter: @Saksham2394

Click here for reuse options!
Copyright 2017 NewsGram

Next Story

Cepheid to Establish Manufacturing Unit for TB Diagnostics in India

Rifampicin is a drug commonly used in treating TB bacteria in first line of treatment

0
The GeneXpert Edge is developed specifically for near-patient testing, to help support a one visit test-and-treat approach.
The GeneXpert Edge is developed specifically for near-patient testing, to help support a one visit test-and-treat approach. (IANS)

Expanding its footprint in India, US-based molecular diagnostics company Cepheid Inc on Thursday announced its plans to establish a manufacturing unit in the country to improve Tuberculosis (TB) diagnostics.

Cepheid’s GeneXpert MTB/RIF test is a closed-cartridge-based system that is easy to operate by minimally trained staff and gives results in approximately two hours, speeding the conventional backlog that used to exist in traditional diagnostic methods.

The new manufacturing unit would produce MTB/RIF test cartridges, contribute to the government’s “Make in India” initiative and thus bringing the company’s global expertise in TB diagnostics to India, the company said in a statement.

As part of the plan, Cepheid also unveiled its latest portable, easy-to-use TB-testing system — the GeneXpert Edge — which is expected to be available in India later this year, the company said.

The GeneXpert Edge is developed specifically for near-patient testing, to help support a one visit test-and-treat approach.

“Cepheid recognises the need for technological advancement and is committed to contributing significantly to India’s goal of TB eradication,” said Peter Farrell, Executive Vice President, Worldwide Commercial Operations, Cepheid.

Cepheid's Xpert MTB/RIF test has the potential to detect Mycobacterium tuberculosis(MTB)
Cepheid’s Xpert MTB/RIF test has the potential to detect Mycobacterium tuberculosis(MTB).

“We are hopeful that GeneXpert Edge will help eliminate delays in TB diagnostics by providing definitive results within hours and facilitating fast and easy last-mile delivery even in the remote villages of India,” he added.

India has nearly one-fourth of the global TB patients and an estimated 4.8 lakh lives are lost every year due to delayed diagnosis and inadequate treatment and there are above 2.5 million new cases of TB every year. The country aims to eradicate TB by 2025.

Approved by the World Health Organisation (WHO) in 2010, more than 1,200 Cepheid’s GeneXpert Systems have been installed in the last two years at various Revised National Tuberculosis Control Programme (RNTCP) sites in the country and more than 2.5 million cartridges were supplied last year at various centres of Central TB Division (CTD).

Also Read: Fruit Bats Identified As Source Of Nipah Virus Outbreak in Kerala

Cepheid’s Xpert MTB/RIF test has the potential to detect Mycobacterium tuberculosis(MTB) and rifampicin-resistance mutations, which are markers for MDR-TB strains in under two hours.

Rifampicin is a drug commonly used in treating TB bacteria in first line of treatment.

Xpert MTB/RIF tests also have excellent negative predictive value, which allows clinicians to manage TB-negative patients more effectively to prevent unnecessary and costly respiratory isolations. (IANS)